These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28498805)

  • 21. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
    Morera DS; Hasanali SL; Belew D; Ghosh S; Klaassen Z; Jordan AR; Wang J; Terris MK; Bollag RJ; Merseburger AS; Stenzl A; Soloway MS; Lokeshwar VB
    J Urol; 2020 Jan; 203(1):62-72. PubMed ID: 31112107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Liang SK; Hsu CC; Song HL; Huang YC; Kuo CW; Yao X; Li CC; Yang HC; Hung YL; Chao SY; Wu SC; Tsai FR; Chen JK; Liao WN; Cheng SC; Tsou TC; Wang IC
    Oncogene; 2021 Jul; 40(30):4847-4858. PubMed ID: 34155349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC)].
    Liu YQ; Guo RH; Liu LK; Gao W; Zhu CJ; Wei J; Shu YQ
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):426-30. PubMed ID: 21875482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer.
    Rinaldetti S; Worst TS; Rempel E; Kriegmair MC; Hartmann A; Porubsky S; Bolenz C; Erben P
    Sci Rep; 2020 Nov; 10(1):20472. PubMed ID: 33235218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High FOXM1 expression was associated with bladder carcinogenesis.
    Liu D; Zhang Z; Kong CZ
    Tumour Biol; 2013 Apr; 34(2):1131-8. PubMed ID: 23325617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
    Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer.
    Wang Y; Kang XL; Zeng FC; Xu CJ; Zhou JQ; Luo DN
    Pathol Res Pract; 2017 Jul; 213(7):766-772. PubMed ID: 28554751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma.
    Wu S; Chen J; Dong P; Zhang S; He Y; Sun L; Zhu J; Cheng Y; Li X; Tang A; Huang Y; Gui Y; Liu C; Yang G; Zhou F; Cai Z; Wang R
    BMC Cancer; 2014 Nov; 14():836. PubMed ID: 25408144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1.
    Roh YG; Mun MH; Jeong MS; Kim WT; Lee SR; Chung JW; Kim SI; Kim TN; Nam JK; Leem SH
    BMB Rep; 2018 Feb; 51(2):98-103. PubMed ID: 29397866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
    Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent copy number variation in IPO11 and prognostic significance of importin-11 overexpression on poor survival.
    Zhao J; Xu W; He M; Zhang Z; Zeng S; Ma C; Sun Y; Xu C
    Oncotarget; 2016 Nov; 7(46):75648-75658. PubMed ID: 27689332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of CEP55, PLK1 and FOXM1 expression in patients with bladder cancer in comparison with healthy individuals.
    Seyedabadi S; Saidijam M; Najafi R; Mousavi-Bahar SH; Jafari M; MohammadGanji S; Mahdavinezhad A
    Cancer Invest; 2018; 36(8):407-414. PubMed ID: 30277841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FoxM1: Repurposing an oncogene as a biomarker.
    Nandi D; Cheema PS; Jaiswal N; Nag A
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):74-84. PubMed ID: 28855104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
    Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
    BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
    Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
    Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.